1
|
Mitsutani M, Matsushita M, Yokoyama M, Morita A, Hano H, Fujikawa T, Tagami T, Moriyama K. Growth hormone directly stimulates GATA2 expression. Growth Horm IGF Res 2024; 74:101572. [PMID: 38281404 DOI: 10.1016/j.ghir.2024.101572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 01/01/2024] [Accepted: 01/22/2024] [Indexed: 01/30/2024]
Abstract
OBJECTIVE GATA2 is a key transcription factor involved in the differentiation and determination of thyrotrophs and gonadotrophs in pituitary and hematopoietic development. However, studies on the upstream ligands of the GATA2 signal transduction pathway have been limited. To identify upstream ligands, we examined growth hormone (GH) as a plausible stimulator. DESIGN We evaluated GH-induced GATA2 expression in murine TtT/GF thyrotrophic pituitary tumor cells and its direct impact on the GHR/JAK/STAT5 pathway using a combination of a reporter assay, real-time quantitative polymerase chain reaction, and western blotting. RESULTS GATA2 expression increased with activated STAT5B in a dose-dependent manner and was inhibited by a STAT5 specific inhibitor. Moreover, we found functional STAT5B binding site consensus sequences at -359 bp in the GATA2 promoter region. CONCLUSION These findings suggest that GH directly stimulates GATA2 via the GHR/JAK/STAT pathway and participates in various developmental phenomena mediated by GATA2.
Collapse
Affiliation(s)
- Mana Mitsutani
- Medicine & Clinical Science, Faculty of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Midori Matsushita
- Medicine & Clinical Science, Faculty of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Mei Yokoyama
- Medicine & Clinical Science, Faculty of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Ayumu Morita
- Medicine & Clinical Science, Faculty of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Hiromi Hano
- Medicine & Clinical Science, Faculty of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Tomomi Fujikawa
- Medicine & Clinical Science, Faculty of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Tetsuya Tagami
- Clinical Research Institute for Endocrine and Metabolic Diseases, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan
| | - Kenji Moriyama
- Medicine & Clinical Science, Faculty of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan; Clinical Research Institute for Endocrine and Metabolic Diseases, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Institute of Biosciences, Mukogawa Women's University, Hyogo 663-8179, Japan.
| |
Collapse
|
2
|
You Z, Wang J, Li F, Hei W, Li M, Guo X, Gao P, Cao G, Cai C, Li B. Uncoupling Protein 3 Promotes the Myogenic Differentiation of Type IIb Myotubes in C2C12 Cells. Genes (Basel) 2023; 14:2049. [PMID: 38002992 PMCID: PMC10671304 DOI: 10.3390/genes14112049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2023] [Revised: 10/30/2023] [Accepted: 11/04/2023] [Indexed: 11/26/2023] Open
Abstract
Uncoupling protein 3 (Ucp3) is an important transporter within mitochondria and is mainly expressed in skeletal muscle, brown adipose tissue and the myocardium. However, the effects of Ucp3 on myogenic differentiation are still unclear. This study evaluated the effects of Ucp3 on myogenic differentiation, myofiber type and energy metabolism in C2C12 cells. Gain- and loss-of-function studies revealed that Ucp3 could increase the number of myotubes and promote the myogenic differentiation of C2C12 cells. Furthermore, Ucp3 promoted the expression of the type IIb myofiber marker gene myosin heavy chain 4 (Myh4) and decreased the expression of the type I myofiber marker gene myosin heavy chain 7 (Myh7). In addition, energy metabolism related to the expression of PPARG coactivator 1 alpha (Pgc1-α), ATP synthase, H+ transportation, mitochondrial F1 complex, alpha subunit 1 (Atp5a1), lactate dehydrogenase A (Ldha) and lactate dehydrogenase B (Ldhb) increased with Ucp3 overexpression. Ucp3 could promote the myogenic differentiation of type IIb myotubes and accelerate energy metabolism in C2C12 cells. This study can provide the theoretical basis for understanding the role of Ucp3 in energy metabolism.
Collapse
Affiliation(s)
- Ziwei You
- College of Animal Science, Shanxi Agricultural University, 1 Mingxian Nanlu, Jinzhong 030801, China; (Z.Y.); (J.W.); (F.L.); (W.H.); (M.L.); (X.G.); (P.G.); (G.C.)
| | - Jieyu Wang
- College of Animal Science, Shanxi Agricultural University, 1 Mingxian Nanlu, Jinzhong 030801, China; (Z.Y.); (J.W.); (F.L.); (W.H.); (M.L.); (X.G.); (P.G.); (G.C.)
| | - Faliang Li
- College of Animal Science, Shanxi Agricultural University, 1 Mingxian Nanlu, Jinzhong 030801, China; (Z.Y.); (J.W.); (F.L.); (W.H.); (M.L.); (X.G.); (P.G.); (G.C.)
| | - Wei Hei
- College of Animal Science, Shanxi Agricultural University, 1 Mingxian Nanlu, Jinzhong 030801, China; (Z.Y.); (J.W.); (F.L.); (W.H.); (M.L.); (X.G.); (P.G.); (G.C.)
| | - Meng Li
- College of Animal Science, Shanxi Agricultural University, 1 Mingxian Nanlu, Jinzhong 030801, China; (Z.Y.); (J.W.); (F.L.); (W.H.); (M.L.); (X.G.); (P.G.); (G.C.)
| | - Xiaohong Guo
- College of Animal Science, Shanxi Agricultural University, 1 Mingxian Nanlu, Jinzhong 030801, China; (Z.Y.); (J.W.); (F.L.); (W.H.); (M.L.); (X.G.); (P.G.); (G.C.)
| | - Pengfei Gao
- College of Animal Science, Shanxi Agricultural University, 1 Mingxian Nanlu, Jinzhong 030801, China; (Z.Y.); (J.W.); (F.L.); (W.H.); (M.L.); (X.G.); (P.G.); (G.C.)
| | - Guoqing Cao
- College of Animal Science, Shanxi Agricultural University, 1 Mingxian Nanlu, Jinzhong 030801, China; (Z.Y.); (J.W.); (F.L.); (W.H.); (M.L.); (X.G.); (P.G.); (G.C.)
| | - Chunbo Cai
- College of Animal Science, Shanxi Agricultural University, 1 Mingxian Nanlu, Jinzhong 030801, China; (Z.Y.); (J.W.); (F.L.); (W.H.); (M.L.); (X.G.); (P.G.); (G.C.)
- Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China
| | - Bugao Li
- College of Animal Science, Shanxi Agricultural University, 1 Mingxian Nanlu, Jinzhong 030801, China; (Z.Y.); (J.W.); (F.L.); (W.H.); (M.L.); (X.G.); (P.G.); (G.C.)
| |
Collapse
|
3
|
Liu K, Li J, Liu M, Hou J. Molecular chaperone GroEL-GroES enhances the soluble expression of biologically active ovine growth hormone in the prokaryotic system. Protein Expr Purif 2022; 195-196:106097. [DOI: 10.1016/j.pep.2022.106097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Revised: 04/01/2022] [Accepted: 04/19/2022] [Indexed: 10/18/2022]
|
4
|
Kumar R, T A, Singothu S, Singh SB, Bhandari V. Uncoupling proteins as a therapeutic target for the development of new era drugs against neurodegenerative disorder. Pharmacotherapy 2022; 147:112656. [DOI: 10.1016/j.biopha.2022.112656] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 01/10/2022] [Accepted: 01/18/2022] [Indexed: 12/21/2022]
|
5
|
Liu J, Tang M, Li T, Su Z, Zhu Z, Dou C, Liu Y, Pei H, Yang J, Ye H, Chen L. Honokiol Ameliorates Post-Myocardial Infarction Heart Failure Through Ucp3-Mediated Reactive Oxygen Species Inhibition. Front Pharmacol 2022; 13:811682. [PMID: 35264952 PMCID: PMC8899544 DOI: 10.3389/fphar.2022.811682] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Accepted: 01/20/2022] [Indexed: 01/31/2023] Open
Abstract
Post-myocardial infarction heart failure (post-MI HF) is one of the leading global causes of death, and current prevention and treatment methods still cannot avoid the increasing incidence. Honokiol (HK) has previously been reported to improve myocardial ischemia/reperfusion injury and reverse myocardial hypertrophy by activating Sirt1 and Sirt3. We suspect that HK may also have a therapeutic effect on post-MI HF. In this study, we aimed to investigate the efficacy and mechanism of HK in the treatment of post-MI HF. We found that HK inhibited myocardial reactive oxygen species (ROS) production, reduced myocardial fibrosis, and improved cardiac function in mice after MI. HK also reduced the abnormality of mitochondrial membrane potential (MMP) and apoptosis of cardiomyocytes caused by peroxide in neonatal cardiomyocytes. RNAseq results revealed that HK restored the transcriptome changes to a certain extent and significantly enhanced the expression of mitochondrial inner membrane uncoupling protein isoform 3 (Ucp3), a protein that inhibits the production of mitochondrial ROS, protects cardiomyocytes, and relieves heart failure after myocardial infarction (MI). In cardiomyocytes with impaired Ucp3 expression, HK cannot protect against the damage caused by peroxide. More importantly, in Ucp3 knockout mice, HK did not change the increase in the ROS level and cardiac function damage after MI. Taken together, our results suggest that HK can increase the expression of the cardioprotective protein Ucp3 and maintain MMP, thereby inhibiting the production of ROS after MI and ameliorating heart failure.
Collapse
Affiliation(s)
- Jianyu Liu
- State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China
| | - Minghai Tang
- State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China
| | - Tao Li
- West China-Washington Mitochondria and Metabolism Center, Department of Anesthesiology, Laboratory of Anesthesiology and Translational Neuroscience Center, West China Hospital of Sichuan University, Chengdu, China
| | - Zhengying Su
- State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China
| | - Zejiang Zhu
- State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China
| | - Caixia Dou
- State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China
| | - Yan Liu
- State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China
| | - Heying Pei
- State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China
| | - Jianhong Yang
- State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China
| | - Haoyu Ye
- State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China
| | - Lijuan Chen
- State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China
- *Correspondence: Lijuan Chen,
| |
Collapse
|
6
|
Watamoto Y, Futawaka K, Hayashi M, Matsushita M, Mitsutani M, Murakami K, Song Z, Koyama R, Fukuda Y, Nushida A, Nezu S, Kuwahara A, Kataoka K, Tagami T, Moriyama K. Insulin-like growth factor-1 directly mediates expression of mitochondrial uncoupling protein 3 via forkhead box O4. Growth Horm IGF Res 2019; 46-47:24-35. [PMID: 31158782 DOI: 10.1016/j.ghir.2019.05.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2018] [Revised: 03/26/2019] [Accepted: 05/21/2019] [Indexed: 01/01/2023]
Abstract
OBJECTIVE The objective of our study was to examine the direct action of insulin-like growth factor-1(IGF-1) signaling on energy homeostasis in myocytes. DESIGN We studied the IGF-1 stimulation of mitochondrial uncoupling protein 3 (UCP3) expression in the HEK 293 derived cell line TSA201, murine C2C12 skeletal muscle myoblasts, and rat L6 skeletal myoblasts. We also investigated the direct effect of IGF-1 on the Insulin/IGF-1 receptor (IGF-1R)/phosphatidylinositol 3 (PI3)-Akt/forkhead box O4 (FOXO4) pathway using a combination of a reporter assay, semi-quantitative polymerase chain reaction, western blotting, and animal experiments. RESULTS We demonstrated that IGF-1 regulates UCP3 expression via phosphorylation of FOXO4, which is a downstream signal transducer of IGF-1. UCP3 expression increased with activated FOXO4 in a dose-dependent manner. We also examined the functional FOXO4 binding site consensus sequences and identified it as the -1922 bp site in the UCP3 promoter region. UCP3 was also found to be concomitantly expressed with IGF-1 during differentiation of C2C12 myoblasts. Our animal experiments showed that high fat diet induced IGF-1 levels which likely influenced UCP3 expression in the skeletal muscle. CONCLUSION Our findings demonstrate that that IGF-1 directly stimulates UCP3 expression via the IGF-1/IGF-1R/PI3-Akt/FOXO4 pathway.
Collapse
Affiliation(s)
- Yukiko Watamoto
- Medicine & Clinical Science, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Kumi Futawaka
- Medicine & Clinical Science, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Misa Hayashi
- Medicine & Clinical Science, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Midori Matsushita
- Medicine & Clinical Science, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Mana Mitsutani
- Medicine & Clinical Science, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Kana Murakami
- Medicine & Clinical Science, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Zilin Song
- Medicine & Clinical Science, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Rie Koyama
- Medicine & Clinical Science, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Yuki Fukuda
- Medicine & Clinical Science, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Ayaka Nushida
- Medicine & Clinical Science, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Syoko Nezu
- Medicine & Clinical Science, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Akiko Kuwahara
- Medicine & Clinical Science, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Kazusaburo Kataoka
- Medicine & Clinical Science, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan
| | - Tetsuya Tagami
- Clinical Research Institute for Endocrine and Metabolic Diseases, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan
| | - Kenji Moriyama
- Medicine & Clinical Science, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo 663-8179, Japan; Clinical Research Institute for Endocrine and Metabolic Diseases, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan.
| |
Collapse
|
7
|
Matsushita M, Futawaka K, Hayashi M, Murakami K, Mitsutani M, Hatai M, Watamoto Y, Yoshikawa N, Nakamura K, Tagami T, Moriyama K. Cigarette Smoke Extract Modulates Functions of Peroxisome Proliferator-Activated Receptors. Biol Pharm Bull 2019; 42:1628-1636. [PMID: 31582651 DOI: 10.1248/bpb.b18-00991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Cigarette smoke extract (CSE) contains many toxicants and may derange the physiological processes, such as cholesterol metabolism. We examined the impact of CSE on transcriptional regulation mediated peroxisome proliferator-activated receptors (PPARs) and its interaction with cofactors to elucidate differences in the molecular mechanism between CSE and other agonists of PPARs. We constructed several mutant PPARs (mPPARs) with amino acid substitution in the ligand-binding domain, which according to the molecular modeling, may affect the binding of agonists. In transient expression assays, each wild-type peroxisome proliferator-activated receptor (PPAR) mediated transcription stimulated by CSE was faintly yet significantly elevated compared to the control. The CSE-induced transcriptional activation was abolished in the H323A, H323Y, S342A, and H449A mPPARγs, although the activation elevated by pioglitazone was reserved. In the mPPARγ with Y473A and mPPARβ/δs with H286Y and Y436A, the pioglitazone-induced or L165041-activated transcriptional elevations were decreased and were lower than that of CSE-induced stimulation. These results suggested that CSE activated both mutant PPARs to be selectively different from those ligands. Mammalian two-hybrid assay illustrated that CSE could mildly recruit SRC1 or GRIP1 to the wild-type PPARγ. Representative ingredients, such as acrolein and crotonaldehyde present in CSE, could stimulate PPAR isoforms even at the toxicological concentrations and might possibly contribute to stimulatory effects. CSE mildly regulates the cholesterol metabolism-related genes, such as low density lipoprotein (LDL) receptor and Liver X receptor (LXR)β. In conclusion, these CSE effects the nuclear hormone receptors and their cofactors thereby disturbing metabolic phenomena. Therefore, CSE might be involved in cholesterol metabolism.
Collapse
Affiliation(s)
- Midori Matsushita
- Department of Medicine and Clinical Science, Graduate School of Pharmaceutical Sciences, Mukogawa Women's University
| | - Kumi Futawaka
- Department of Medicine and Clinical Science, Graduate School of Pharmaceutical Sciences, Mukogawa Women's University
| | - Misa Hayashi
- Department of Medicine and Clinical Science, Graduate School of Pharmaceutical Sciences, Mukogawa Women's University
| | - Kana Murakami
- Department of Medicine and Clinical Science, Graduate School of Pharmaceutical Sciences, Mukogawa Women's University
| | - Mana Mitsutani
- Department of Medicine and Clinical Science, Graduate School of Pharmaceutical Sciences, Mukogawa Women's University
| | - Mayuko Hatai
- Department of Medicine and Clinical Science, Graduate School of Pharmaceutical Sciences, Mukogawa Women's University
| | - Yukiko Watamoto
- Department of Medicine and Clinical Science, Graduate School of Pharmaceutical Sciences, Mukogawa Women's University
| | - Noriko Yoshikawa
- Department of Medicine and Clinical Science, Graduate School of Pharmaceutical Sciences, Mukogawa Women's University
| | - Kazuki Nakamura
- Department of Medicine and Clinical Science, Graduate School of Pharmaceutical Sciences, Mukogawa Women's University
| | - Tetsuya Tagami
- Division of Endocrinology, Metabolism and Hypertension, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization
| | - Kenji Moriyama
- Department of Medicine and Clinical Science, Graduate School of Pharmaceutical Sciences, Mukogawa Women's University
- Division of Endocrinology, Metabolism and Hypertension, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization
| |
Collapse
|